ApoB, Lp(a), and hsCRP: The Advanced Cardiac Labs Your Doctor Should Order

If your doctor recently told you your cholesterol "looks fine," you might want to ask a few more questions. The standard lipid panel, the test that's been the cornerstone of cardiovascular risk assessment for decades, misses a significant portion of people who will go on to have heart attacks.

This isn't a fringe opinion. It's established science. And yet, most physicians continue to rely almost exclusively on LDL cholesterol to guide treatment decisions, leaving patients with an incomplete and sometimes dangerously misleading picture of their actual risk.

At Griffin Concierge Medical in Tampa and St. Petersburg, we take a different approach. Our advanced cardiac lab panel includes biomarkers that the research shows are more predictive than standard cholesterol, and that most primary care practices don't routinely order.

Approximately half of all heart attacks occur in people with "normal" LDL cholesterol levels.

When you get a standard lipid panel, the lab reports total cholesterol, LDL-C, HDL-C, and triglycerides. LDL-C has traditionally been considered the primary target for reducing cardiovascular risk.

LDL-C measures the weight of cholesterol carried by LDL particles, not the number of particles themselves. Imagine predicting traffic congestion by total vehicle weight rather than car count—a single semi-truck weighs as much as 20 sedans but occupies one lane. What causes atherosclerosis is the number of particles, not their cargo.

Two patients can have identical LDL-C levels but very different numbers of LDL particles. The patient with more particles has more opportunities for particles to penetrate the artery wall and initiate plaque formation.

Apolipoprotein B is the protein that wraps around every atherogenic lipoprotein particle—LDL, VLDL, IDL, and Lp(a). Each carries exactly one ApoB molecule. Measuring ApoB gives a direct count of particles capable of depositing cholesterol in artery walls.

A 2019 analysis in JAMA Cardiology of nearly 400,000 participants found ApoB was a stronger predictor of cardiovascular events than LDL-C. The European Atherosclerosis Society now recommends ApoB as the preferred marker for assessing cardiovascular risk.

Lipoprotein(a) is an LDL-like particle with an additional protein that makes it both more inflammatory and more likely to promote clot formation than regular LDL.

Your Lp(a) level is 80–90% genetically determined. Unlike LDL cholesterol, Lp(a) doesn't respond meaningfully to diet, exercise, or most cholesterol-lowering medications including statins. Your Lp(a) at age 25 will be roughly the same at age 65.

Approximately 20% of the population has elevated Lp(a), defined as above 50 mg/dL or 125 nmol/L. These individuals have significantly increased risk of heart attack, stroke, and aortic valve disease, independent of other risk factors. Because Lp(a) is genetically fixed, you only need to test it once in your lifetime.

If your Lp(a) is elevated, you can't change it directly—but you can compensate by being more aggressive with the risk factors you can control: targeting a lower ApoB, being more vigilant about blood pressure, or considering earlier imaging.

Atherosclerosis is fundamentally an inflammatory disease. The plaques that rupture and cause heart attacks are typically inflamed plaques characterized by immune cell infiltration and structural instability. High-sensitivity CRP is a marker of systemic inflammation that helps identify ongoing vascular inflammation.

The JUPITER trial demonstrated that patients with low LDL-C but elevated hsCRP still benefited significantly from statin therapy. The CANTOS trial showed directly targeting inflammation reduced cardiovascular events even without lowering LDL.

When HDL is in the 20s or 30s combined with triglycerides above 150 mg/dL—especially in younger patients—it signals underlying metabolic dysfunction: insulin resistance, impaired fat metabolism, and an inflammatory state that accelerates atherosclerosis.

Homocysteine is an amino acid that when elevated is associated with endothelial dysfunction, increased clotting tendency, and accelerated atherosclerosis. Elevated levels are often correctable with targeted B vitamin supplementation (methylfolate, methylcobalamin, P5P).

No single biomarker tells the whole story. Cardiovascular disease develops through multiple pathways, and a comprehensive assessment addresses lipid accumulation, inflammation, endothelial injury, and genetic predisposition.

When appointments are longer and panel sizes are smaller, there's space to practice the kind of thorough, evidence-based preventive care that these advanced biomarkers enable.